Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
Part of paid clinical trials in Kansas City, Kansas.
- Sponsor
- University of Kansas Medical Center
- Study ID
- NCT06985225
- Status
- Recruiting
Conditions
- COPD
- Cystic Fibrosis (CF)
- Non-CF Bronchiectasis
- Severe Asthma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Hyperpolarized 129 Xenon — COMBINATION_PRODUCTXenon gas contrast agent for MRI
Study Details
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
Key Dates
- First listed
- May 22, 2025
- Start date
- Jun 1, 2025
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 8 participants (estimated)
Arms
- Arm: Main GroupPatients with Severe Asthma with a high T2 phenotype
Primary Outcome Measure
Ventilation Defect in Mucus blocked Regions [ Time Frame: Baseline ]
Central Contacts
- Cristal Monge(913) 945-9399
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | Peter Niedbalski, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Kansas City, KS
By specialty
By research site
Related Studies
- Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary DiseasePHASE1 · Recruiting · Mario Castro, MD, MPH · Kansas City, Kansas
- A Study to Evaluate Solrikitug in Participants With COPD (ZION)PHASE2 · Recruiting · Uniquity One (UNI) · Birmingham, Alabama
- Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3Recruiting · Apreo Health, Inc. · Birmingham, Alabama
- Phase 2 Study to Assess the Safety and Efficacy of ANG003PHASE2 · Recruiting · Anagram Therapeutics, Inc. · Long Beach, California